US approves Regeneron antibody treatment given to Trump

The US Food and Drug Administration hopes authorisation of the Regen-Cov2 antibody treatment for Covid-19 will reduce hospitalisation and the burden on the healthcare system. – AFP pic, November 22, 2020.

A COVID-19 antibody therapy used to treat President Donald Trump was approved by the US drug regulator yesterday for people who aren’t yet hospitalised by the disease but are at high risk.

The green light for drugmaker Regeneron came after Regen-Cov2, a combination of two lab-made antibodies, was shown to reduce Covid-19-related hospitalisations or emergency room visits in patients with underlying conditions.

Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!

Subscribe Now!

Sign up or sign in here to comment.